Get the Stockscreener App
1.44
2.70%
-0.04
After Hours:
1.37
-0.07
-4.86%
Galmed Pharmaceuticals Ltd stock is traded at $1.44, with a volume of 142.78K.
It is down -2.70% in the last 24 hours and down -30.10% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.48
Open:
$1.4106
24h Volume:
142.78K
Relative Volume:
0.48
Market Cap:
$7.86M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4417
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
-0.69%
1M Performance:
-30.10%
6M Performance:
-45.04%
1Y Performance:
-59.02%
1-Day Range:
$1.40
$1.47
1-Week Range:
$1.38
$1.5383
52-Week Range:
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.44 | 8.08M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Does Galmed Pharmaceuticals Ltd. have strong fundamentalsRate Hike & High Conviction Buy Zone Picks - thegnnews.com
What machine learning models say about Galmed Pharmaceuticals Ltd.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
What makes Galmed Pharmaceuticals Ltd. stock price move sharplyQuarterly Growth Report & Reliable Trade Execution Plans - thegnnews.com
What’s next for Galmed Pharmaceuticals Ltd. stock pricePortfolio Gains Report & Reliable Breakout Stock Forecasts - Newser
How Galmed Pharmaceuticals Ltd. stock performs during market volatilityEarnings Miss & Long-Term Growth Stock Strategies - Newser
Can Galmed Pharmaceuticals Ltd. hit a new high this monthJuly 2025 Market Mood & Precise Buy Zone Tips - Newser
Why Galmed Pharmaceuticals Ltd. is moving todayWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
Analyzing Galmed Pharmaceuticals Ltd. with multi timeframe chartsTrade Risk Summary & Free High Return Stock Watch Alerts - Newser
Is Galmed Pharmaceuticals Ltd. still worth holding after the dipGlobal Markets & Entry Point Confirmation Signals - Newser
Volatility clustering patterns for Galmed Pharmaceuticals Ltd.Market Movers & Free Real-Time Volume Trigger Notifications - Newser
Galmed Pharmaceuticals Amends Articles of Association Following Shareholder Approval - TipRanks
How moving averages guide Galmed Pharmaceuticals Ltd. tradingPrice Action & Reliable Entry Point Trade Alerts - Newser
Historical volatility pattern of Galmed Pharmaceuticals Ltd. visualizedJuly 2025 Opening Moves & Technical Buy Zone Confirmations - Newser
Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum - TipRanks
Is Galmed Pharmaceuticals Ltd. Stock a Good Fit for Conservative InvestorsChart Pattern Strategy with ROI Focus - Newser
Is Galmed Pharmaceuticals Ltd. showing signs of accumulationFree Stock Screener With Smart Filters - Newser
How to recover losses in Galmed Pharmaceuticals Ltd. stockDaily Technical Chart Pattern Analysis Report - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Raised to Hold at Wall Street Zen - Defense World
Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expands By 49.9% - Defense World
Quantitative breakdown of Galmed Pharmaceuticals Ltd. recent moveVolume Spike Detection for Early Breakouts - Newser
What moving averages say about Galmed Pharmaceuticals Ltd.Swing Trade Watchlist with Entry Zones - Newser
Short Term Trend Reversal in Galmed Pharmaceuticals Ltd. PossibleHigh Accuracy Alerts for ROI Traders Detected - beatles.ru
Technical signs of recovery in Galmed Pharmaceuticals Ltd.High Conviction Stock Long-Term Summary - Newser
Investors Hope for Bounce in Galmed Pharmaceuticals Ltd. After Selloff - metal.it
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):